Tags

Type your tag names separated by a space and hit enter

Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results.
Euro Surveill. 2014 Jul 10; 19(27):5-13.ES

Abstract

The effectiveness of the 2012/13 trivalent seasonal influenza vaccine (TIV) was assessed using a test-negative case-control study of patients consulting primary care with influenza-like illness in the United Kingdom. Strain characterisation was undertaken on selected isolates. Vaccine effectiveness (VE) against confirmed influenza A(H3N2), A(H1N1) and B virus infection, adjusted for age, sex, surveillance scheme (i.e. setting) and month of sample collection was 26% (95% confidence interval (CI): -4 to 48), 73% (95% CI: 37 to 89) and 51% (95% CI: 34 to 63) respectively. There was an indication, although not significant, that VE declined by time since vaccination for influenza A(H3N2) (VE 50% within three months, 2% after three months, p=0.25). For influenza A(H3N2) this is the second season of low VE, contributing to the World Health Organization (WHO) recommendation that the 2013/14 influenza vaccine strain composition be changed to an A(H3N2) virus antigenically like cell-propagated prototype 2012/13 vaccine strain (A/Victoria/361/2011). The lower VE seen for type B is consistent with antigenic drift away from the 2012/13 vaccine strain. The majority of influenza B viruses analysed belong to the genetic clade 2 and were antigenically distinguishable from the 2012/13 vaccine virus B/Wisconsin/1/2010 clade 3. These findings supported the change to the WHO recommended influenza B vaccine component for 2013/14.

Authors+Show Affiliations

Public Health England Health Protection Directorate, Colindale, London, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25033051

Citation

Andrews, N, et al. "Effectiveness of Trivalent Seasonal Influenza Vaccine in Preventing Laboratory-confirmed Influenza in Primary Care in the United Kingdom: 2012/13 End of Season Results." Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, vol. 19, no. 27, 2014, pp. 5-13.
Andrews N, McMenamin J, Durnall H, et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Euro Surveill. 2014;19(27):5-13.
Andrews, N., McMenamin, J., Durnall, H., Ellis, J., Lackenby, A., Robertson, C., von Wissmann, B., Cottrell, S., Smyth, B., Moore, C., Gunson, R., Zambon, M., Fleming, D., & Pebody, R. (2014). Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 19(27), 5-13.
Andrews N, et al. Effectiveness of Trivalent Seasonal Influenza Vaccine in Preventing Laboratory-confirmed Influenza in Primary Care in the United Kingdom: 2012/13 End of Season Results. Euro Surveill. 2014 Jul 10;19(27):5-13. PubMed PMID: 25033051.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. AU - Andrews,N, AU - McMenamin,J, AU - Durnall,H, AU - Ellis,J, AU - Lackenby,A, AU - Robertson,C, AU - von Wissmann,B, AU - Cottrell,S, AU - Smyth,B, AU - Moore,C, AU - Gunson,R, AU - Zambon,M, AU - Fleming,D, AU - Pebody,R, Y1 - 2014/07/10/ PY - 2014/7/18/entrez PY - 2014/7/18/pubmed PY - 2014/9/3/medline SP - 5 EP - 13 JF - Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin JO - Euro Surveill VL - 19 IS - 27 N2 - The effectiveness of the 2012/13 trivalent seasonal influenza vaccine (TIV) was assessed using a test-negative case-control study of patients consulting primary care with influenza-like illness in the United Kingdom. Strain characterisation was undertaken on selected isolates. Vaccine effectiveness (VE) against confirmed influenza A(H3N2), A(H1N1) and B virus infection, adjusted for age, sex, surveillance scheme (i.e. setting) and month of sample collection was 26% (95% confidence interval (CI): -4 to 48), 73% (95% CI: 37 to 89) and 51% (95% CI: 34 to 63) respectively. There was an indication, although not significant, that VE declined by time since vaccination for influenza A(H3N2) (VE 50% within three months, 2% after three months, p=0.25). For influenza A(H3N2) this is the second season of low VE, contributing to the World Health Organization (WHO) recommendation that the 2013/14 influenza vaccine strain composition be changed to an A(H3N2) virus antigenically like cell-propagated prototype 2012/13 vaccine strain (A/Victoria/361/2011). The lower VE seen for type B is consistent with antigenic drift away from the 2012/13 vaccine strain. The majority of influenza B viruses analysed belong to the genetic clade 2 and were antigenically distinguishable from the 2012/13 vaccine virus B/Wisconsin/1/2010 clade 3. These findings supported the change to the WHO recommended influenza B vaccine component for 2013/14. SN - 1560-7917 UR - https://www.unboundmedicine.com/medline/citation/25033051/Effectiveness_of_trivalent_seasonal_influenza_vaccine_in_preventing_laboratory_confirmed_influenza_in_primary_care_in_the_United_Kingdom:_2012/13_end_of_season_results_ L2 - http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20851 DB - PRIME DP - Unbound Medicine ER -